A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J’s drug/device combination product, Inlexzo, came from its 2019 acquisition of Taris Biomedical.
The post FDA Nod for J&J’s Drug/Device Treatment Gives Bladder Cancer Patients Another Option appeared first on MedCity News.
